mva-mbn32
Vaccineexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00386633)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva-mbn32
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00428337 | Phase 1 | Apr 1, 2007 | Bavarian Nordic, Epimmune, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), St. Louis University, University of Rochester |
| NCT00390078 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | Bavarian Nordic, National Institutes of Health (NIH) |
| NCT00386633 | Phase 1 | Oct 1, 2006 | Bavarian Nordic |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bavarian Nordic | For profit | 3 | 2 | 2 | 2006 |
| Epimmune | For profit | 1 | 0 | 1 | 2007 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2007 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2007 |
| St. Louis University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2007 |
7 organizations
Page 1 / 1